Top Immunotherapy Companies
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Oncolytics Biotech: A New Paradigm in Immuno-oncology Therapy

Top 10 Immunotherapy Companies - 2020

The emergence of immunotherapy is opening up treatment options for an increasing number of previously incurable diseases. Unfortunately, despite the growing popularity of immunotherapy, those who respond to the treatment remain in the minority. Finding new ways to identify and stratify patients who are the most likely to respond to specific immunotherapeutic approaches, therefore, is now a primary focus in the field.

Understanding a patient’s immunogenic responses can offer essential insights needed to guide immunotherapeutic treatment decisions. Advances in the imaging arena, such as the real-time, noninvasive visualization of specific cells, or the application of artificial intelligence (AI) in pathology, have garnered recent attention in the immunotherapy space. For instance, an artificial intelligence algorithm can detect previously unseen changes in CT scans patterns and determine how well patients with lung cancer would benefit from immunotherapy.

Additionally, while cell therapies hold great promise clinically, high manufacturing costs relative to reimbursement present a formidable roadblock to commercialization. The need for process efficiency, product consistency, and cost-effectiveness is driving automation efforts in numerous cell therapy fields, particularly for T-cell immunotherapies. To that end, a single-cell proteomics system can be used together to advance the future of T-cell immunotherapy. Each is a closed, fully automated bench top system that does not require numerous personnel and extensive training to run. Together, these next-generation platforms pave the way for decentralized manufacturing of novel cell therapies and a solution for complete functional characterization of each cell in a cell therapy product, to ensure correlative functional potency of the manufactured cell product.

At this juncture, there is a wide variety of immunotherapy companies entering the industry with a set of advanced and integrated immunotherapy solutions and service offerings. To help companies navigate through the best-of-breed immunotherapy companies, Pharma Tech Outlook has compiled a list of the top 10 immunotherapy companies. The enlisted organizations are transforming immunotherapy processes and treatments at the intersection of various disruptive technologies. Besides, the magazine also comprises insights from thought leaders in the sector on the industry trends, best practices, recent innovations, and their advice for the aspiring CIOs and CXOs.

We present to you Pharma Tech Outlook’s, “Top 10 Immunotherapy Companies – 2020.”

Top Immunotherapy Companies

BennuBio is an emerging biotechnology company that offers Velocyt, a parallel flow cytometer that eliminates the technical constraints of traditional flow cytometers in the rare cell analysis. Instead of using sheath fluids, Velocyt uses standing acoustic waves to focus a sample directly into 10 parallel particle streams without sample dilution. These streams intersect line-focused lasers, and these intersections are imaged using a high-speed camera. Software converts the images into flow cytometry data. The Velocyt design simplifies workflows by eliminating washing, lysing, and concentration steps, and analyzes samples at 10 mL/min and >100K events/sec

www.bennubio.com

Cytek Biosciences’ flow cytometry systems represent the first big technological leap in flow cytometry in decades. The full spectrum optics technology onboard enables the ability to use 40 cellular markers and beyond to phenotype cell populations in a heterogeneous sample, providing scientists in academia, biotechnology and pharmaceuticals with a powerful tool for characterizing the immune system’s response to cancer. That information can then be used to improve patient treatments

cytekbio.com

Genocea is on a mission to develop better cancer immunotherapies through better antigen selection. Standing on a firm belief that “targets matter,” Genocea advocates the necessity of selecting the right neoantigens to drive immune responses in cancer patients. Genocea’s approach identifies the neoantigens to which patients’ T cells can mount anti-tumor T cell responses, and designs its immunotherapies to amplify such responses in order to attack the tumor better. This wherewithal to break new ground in cancer treatment is a by-product of years of research and development and the rich expertise that Genocea brings to the table

www.genocea.com

Kineta has set a simple yet powerful mission of developing novel immuno-therapies that transform patients’ lives. The company leverages its expertise in immunology to create a pipeline of investigational drugs and pave the way for the next-gen immunotherapies by focusing on innate immunity. Kineta is currently developing a novel anti-VISTA antibody for the treatment of solid tumors. This antibody may turn immunosuppressive cells into inflammatory or immuno reactive ones, increase effect or T cell (Teff) migration and tumor infiltration and drive anti-tumor responses. The clinical trial of this antibody will begin in 2021

kinetabio.com

Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and haematological malignancies. The virus is classified as Biosafety Level-2 and is relatively safe to handle in laboratory environments with accidental exposure causing only mild side effects with symptoms such as a common cold or the flu

www.oncolyticsbiotech.com

Orion Biotechnology is a Canadian based specialty pharmaceutical company, pioneering the development of a new class of immunotherapeutics. Orion focuses on discovering and developing a best-in-class drug with its Drug Discovery Platform, which is based on the precision engineering of small proteins. This proprietary platform enables Orion to generate new peptide and protein analogs rapidly, systematically, and cost-effectively compared to traditional modalities.Behind the incredible achievements of Orion is a team that includes scientific and clinical experts needed for the development of drugs. More so, the company has business experts to handle the commercial aspect of developing and bringing the drugs to market

orionbiotechnology.com

BioXcel

BioXcel

Bioxcel Corporation is a biopharmaceutical company pioneering the application of artificial intelligence and big data analytics integrated with drug development expertise. We use our proprietary platforms to advance the next wave of medicines and significantly improve the clinical and regulatory success of drug development. Our goal is to develop innovative medicines in immuno-oncology, neuroscience, and rare diseases with high unmet need. We believe that our Research & Development Engine can result in a disruptive change that will impact pharma productivity and innovation to benefit the entire healthcare ecosystem

Immunovant

Immunovant

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases

Moderna

Moderna

We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured. Since our founding in 2010, we have worked to build the industry's leading mRNA technology platform, the infrastructure to accelerate drug discovery and early development, a rapidly expanding pipeline, and a world-class team. Our pipeline includes development candidates for mRNA-based vaccines and therapies spanning several therapeutic areas, and we have multiple clinical trials underway with other development candidates progressing toward the clinic. In addition, we have numerous discovery programs advancing toward development

VBI Vaccines

VBI Vaccines

VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with the only tri-antigenic hepatitis B vaccine, Sci-B-Vac®, which is approved for use and commercially available in Israel, and recently completed its Phase 3 program in the U.S., Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI’s lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic pan-coronavirus vaccine candidate. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel